Successes and failures of chemokine-pathway targeting in rheumatoid arthritis

Targeting cell migration in rheumatoid arthritis

(2015) Darren L. Asquith et al.   CURRENT OPINION IN RHEUMATOLOGY

CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis

(2015) Jhimmy Talbot et al.   Arthritis & Rheumatology

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

(2014) D L Boyle et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibitors of angiogenesis: Ready for prime time?

(2014) Chrissta X. Maracle et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4

(2014) James Edward Pease et al.   Expert Opinion on Drug Discovery

The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens

(2014) Chris AH Hansell et al.   IMMUNOLOGY AND CELL BIOLOGY

Inhibition of Monocyte Chemoattractant Protein-1 Ameliorates Rat Adjuvant-Induced Arthritis

(2014) S. Shahrara et al.   JOURNAL OF IMMUNOLOGY

Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis

(2014) Joseph B. Santella et al.   JOURNAL OF MEDICINAL CHEMISTRY

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice

(2014) Waka Yokoyama et al.   ARTHRITIS RESEARCH & THERAPY

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

(2014) Stinne Ravn Greisen et al.   ARTHRITIS RESEARCH & THERAPY

Citrullination of Epithelial Neutrophil-Activating Peptide 78/CXCL5 Results in Conversion From a Non-Monocyte-Recruiting Chemokine to a Monocyte-Recruiting Chemokine

(2014) Ken Yoshida et al.   Arthritis & Rheumatology

Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

(2013) C. Zhong et al.   CLINICAL CANCER RESEARCH

Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease

(2013) Donna K. Finch et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Small Molecule Inhibitors of CXCR4

(2013) Bikash Debnath et al.   Theranostics

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

(2012) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection

(2012) Chung-Her Jenh et al.   BMC IMMUNOLOGY

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

(2012) Dona L Fleishaker et al.   ARTHRITIS RESEARCH & THERAPY

Characterization of CCL19 and CCL21 in rheumatoid arthritis

(2011) Sarah R. Pickens et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

(2011) Michael Yellin et al.   ARTHRITIS AND RHEUMATISM

Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

(2011) D J Dairaghi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis

(2011) Maria C. Lebre et al.   PLoS One

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist

(2011) Chu-Biao Xue et al.   ACS Medicinal Chemistry Letters

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial

(2010) A. W. R. van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate

(2010) Daniëlle M. Gerlag et al.   ARTHRITIS AND RHEUMATISM

Pathogenic role of CXCR7 in rheumatoid arthritis

(2010) Kaori Watanabe et al.   ARTHRITIS AND RHEUMATISM

Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases

(2010) Qihong Zhao   JOURNAL OF LEUKOCYTE BIOLOGY

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

(2009) Clarissa E. Vergunst et al.   ARTHRITIS AND RHEUMATISM

Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody

(2009) Pierre Portalès et al.   IMMUNOLOGY

Proinflammatory Cytokines Synergistically Enhance the Production of Chemokine Ligand 20 (CCL20) from Rheumatoid Fibroblast-like Synovial Cells in vitro and Serum CCL20 Is Reduced in vivo by Biologic Disease-modifying Antirheumatic Drugs

(2009) S.-Y. KAWASHIRI et al.   JOURNAL OF RHEUMATOLOGY

Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5

(2009) S. E. Hall et al.   MOLECULAR PHARMACOLOGY

Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint

(2008) Antonio Manzo et al.   ARTHRITIS AND RHEUMATISM

Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial

(2008) Clarissa E. Vergunst et al.   ARTHRITIS AND RHEUMATISM

Noncompetitive Antagonism and Inverse Agonism as Mechanism of Action of Nonpeptidergic Antagonists at Primate and Rodent CXCR3 Chemokine Receptors

(2008) D. Verzijl et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Chemokine receptor antagonists: overcoming developmental hurdles

(2008) Richard Horuk   NATURE REVIEWS DRUG DISCOVERY

Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats

(2007) M M Barsante et al.   BRITISH JOURNAL OF PHARMACOLOGY